AZNAstraZenecaRunning, no new patients
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
Advanced or Metastatic Non-Small Cell Lung Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Oct 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 594 (final count)
- Started
- Sep 15, 2022
- Main results expected
- Oct 6, 2025
- Fully finished
- Dec 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: Every 3 months (± 1 week) following objective progression of disease (PD) or treatment discontinuation (up to three years)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-10-06, no fading
Raw record changes
- none yet
Trial ID NCT05450692 · record last updated 2026-07-13 · checked 2026-11-09 15:47 UTC